569 related articles for article (PubMed ID: 26923955)
1. [Gene therapy using retrovirus vectors: vector development and biosafety at clinical trials].
Doi K; Takeuchi Y
Uirusu; 2015; 65(1):27-36. PubMed ID: 26923955
[TBL] [Abstract][Full Text] [Related]
2. Biosafety challenges for use of lentiviral vectors in gene therapy.
Rothe M; Modlich U; Schambach A
Curr Gene Ther; 2013 Dec; 13(6):453-68. PubMed ID: 24195603
[TBL] [Abstract][Full Text] [Related]
3. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production.
Sinn PL; Sauter SL; McCray PB
Gene Ther; 2005 Jul; 12(14):1089-98. PubMed ID: 16003340
[TBL] [Abstract][Full Text] [Related]
4. Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients.
Marcucci KT; Jadlowsky JK; Hwang WT; Suhoski-Davis M; Gonzalez VE; Kulikovskaya I; Gupta M; Lacey SF; Plesa G; Chew A; Melenhorst JJ; Levine BL; June CH
Mol Ther; 2018 Jan; 26(1):269-279. PubMed ID: 29203150
[TBL] [Abstract][Full Text] [Related]
5. Genetic modification of lymphocytes by retrovirus-based vectors.
Suerth JD; Schambach A; Baum C
Curr Opin Immunol; 2012 Oct; 24(5):598-608. PubMed ID: 22995202
[TBL] [Abstract][Full Text] [Related]
6. Biosafety considerations using gamma-retroviral vectors in gene therapy.
Deichmann A; Schmidt M
Curr Gene Ther; 2013 Dec; 13(6):469-77. PubMed ID: 24195605
[TBL] [Abstract][Full Text] [Related]
7. Retrovirus and lentivirus vector design and methods of cell conditioning.
Cooray S; Howe SJ; Thrasher AJ
Methods Enzymol; 2012; 507():29-57. PubMed ID: 22365768
[TBL] [Abstract][Full Text] [Related]
8. The retroviral vector family: something for everyone.
Elsner C; Bohne J
Virus Genes; 2017 Oct; 53(5):714-722. PubMed ID: 28762206
[TBL] [Abstract][Full Text] [Related]
9. Insertional gene activation by lentiviral and gammaretroviral vectors.
Bokhoven M; Stephen SL; Knight S; Gevers EF; Robinson IC; Takeuchi Y; Collins MK
J Virol; 2009 Jan; 83(1):283-94. PubMed ID: 18945765
[TBL] [Abstract][Full Text] [Related]
10. Monitoring for potential adverse effects of prenatal gene therapy: genotoxicity analysis in vitro and on small animal models ex vivo and in vivo.
Themis M
Methods Mol Biol; 2012; 891():341-70. PubMed ID: 22648780
[TBL] [Abstract][Full Text] [Related]
11. Lentiviral vectors and gene therapy.
Klimatcheva E; Rosenblatt JD; Planelles V
Front Biosci; 1999 Jun; 4():D481-96. PubMed ID: 10352135
[TBL] [Abstract][Full Text] [Related]
12. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity.
Modlich U; Bohne J; Schmidt M; von Kalle C; Knöss S; Schambach A; Baum C
Blood; 2006 Oct; 108(8):2545-53. PubMed ID: 16825499
[TBL] [Abstract][Full Text] [Related]
13. In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors.
Bauer G; Dao MA; Case SS; Meyerrose T; Wirthlin L; Zhou P; Wang X; Herrbrich P; Arevalo J; Csik S; Skelton DC; Walker J; Pepper K; Kohn DB; Nolta JA
Mol Ther; 2008 Jul; 16(7):1308-15. PubMed ID: 18461052
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of retroviral integration and mutagenesis.
Cavazza A; Moiani A; Mavilio F
Hum Gene Ther; 2013 Feb; 24(2):119-31. PubMed ID: 23330935
[TBL] [Abstract][Full Text] [Related]
15. Unique integration profiles in a canine model of long-term repopulating cells transduced with gammaretrovirus, lentivirus, or foamy virus.
Beard BC; Keyser KA; Trobridge GD; Peterson LJ; Miller DG; Jacobs M; Kaul R; Kiem HP
Hum Gene Ther; 2007 May; 18(5):423-34. PubMed ID: 17518616
[TBL] [Abstract][Full Text] [Related]
16. Clinical application of lentiviral vectors - concepts and practice.
Schambach A; Baum C
Curr Gene Ther; 2008 Dec; 8(6):474-82. PubMed ID: 19075630
[TBL] [Abstract][Full Text] [Related]
17. Retroviral vectors: post entry events and genomic alterations.
Nowrouzi A; Glimm H; von Kalle C; Schmidt M
Viruses; 2011 May; 3(5):429-55. PubMed ID: 21994741
[TBL] [Abstract][Full Text] [Related]
18. Novel principles of gamma-retroviral insertional transcription activation in murine leukemia virus-induced end-stage tumors.
Sokol M; Wabl M; Ruiz IR; Pedersen FS
Retrovirology; 2014 May; 11():36. PubMed ID: 24886479
[TBL] [Abstract][Full Text] [Related]
19. Integration of retroviral vectors.
Gabriel R; Schmidt M; von Kalle C
Curr Opin Immunol; 2012 Oct; 24(5):592-7. PubMed ID: 22981243
[TBL] [Abstract][Full Text] [Related]
20. [Progress in improvement of lentiviral vectors' transcriptional read-through].
He J; Zhang J
Sheng Wu Gong Cheng Xue Bao; 2011 Nov; 27(11):1541-8. PubMed ID: 22393708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
